genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2023
Bellicum Pharmaceuticals
News
StockWatch: Icahn Pursues Illumina Board Seats, and a Sell-Off of Grail
Cancer
FDA Imposes Clinical Hold on Bellicum Lead Candidate BPX-501
Cancer
Astellas Licenses Cancer Target PSCA to Bellicum
Cancer
Bellicum to Pay Ariad $50M in Revised Cell-Signaling Tech Agreement
Insights
Drug Candidates on Trial
Insights
People in the News
Cancer
Bellicum Raises $20M to Progress Cell Transplant and Cancer Vaccine Products
Cancer
Ariad Inks Three Separate Deals Covering Argent Technology
Cancer
Bellicum Raises $4.5M to Support Prostate Cancer Therapy Program
News
Ariad Licenses Argent Technology for Cancer Therapies
Scroll Up
Scroll Up
